Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Insightec

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Insightec

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name Insightec. It includes 1 original PMA approval. 3 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 11, 2016 to Sep 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code POH appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P150038, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 5 Nahum Heth St., Tirat Carmel, 39120. Recorded on P150038/S044, decision dated Sep 16, 2026.

Changes described in PMA records

P150038/S044: Exablate Model 4000 System

The FDA record P150038/S044, dated 2026-09-16, is an approval of a normal 180-day-track supplement without user fee for the Exablate Model 4000 System, a magnetic-resonance-guided focused ultrasound device under product code POH (Neurology), submitted by Insightec. The supplement's stated reason is a location change covering manufacturer, sterilizer, packager or supplier, and its statement concerns a manufacturing site at Molded Rubber and Plastics Corporation, 13161 W. Glendale Avenue, Butler, WI 53007, USA.

That new Wisconsin location is described as an additional manufacturing site for the Exablate 4000 Treatment Kits. The supplement number identifies it as a change to the original P150038 approval rather than an original PMA, and approving a site is not an approval of the whole system or an independent finding of safety or clinical effectiveness; the record supplies no detail on qualification, inspection or validation of the site, the materials handled there, or any clinical or labeling consequences.

Specific information absent from the supplied fields includes what the kits contain, what operations occur at Butler, and whether the existing manufacturing site or sites remain unchanged.

FDA approval-order wording

approval for a manufacturing site located at Molded Rubber and Plastics Corporation, 13161 W. Glendale Avenue, Butler, WI 53007, USA. This new site will be an additional manufacturing site for the Exablate 4000 Treatment Kits.

Sep 16, 2026 · Normal 180 Day Track No User Fee

P150038/S041: EXABLATE

FDA’s recorded scope: Approval of the post-approval study (PAS) to comply with the conditions of approval outlined in our approval order for P150038/S037.

Mar 23, 2026 · Normal 180 Day Track No User Fee

P150038: EXABLATE

FDA’s recorded scope: Approval for the ExAblate Model 4000 Type 1.0 System (ExAblate Neuro). This device is indicated for use in the unilateral Thalamotomy treatment of idiopathic Essential Tremor patients with medication-refractory tremor. Patients must be at least age 22. The designated area in the brain responsible for the movement disorder symptoms (ventralis intermedius) must be identified and accessible for targeted thermal ablation by the ExAblate device.

Jul 11, 2016

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
InsightecPMA supplementSep 16, 2026FDA
EXABLATEP150038/S041
InsightecPMA supplementMar 23, 2026FDA
InsightecPMA supplementMar 5, 2026FDA
InsightecPMA supplementJan 28, 2026FDA
EXABLATEP150038
InsightecPMA approvalJul 11, 2016FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.